Our breakthrough, proprietary technology platform engineered to enhance drug absorption
End-to-end, in-house control of formulation, development, and manufacturing capabilities
Our proprietary cannabinoid composition for the management of pain and inflammation
Partnering with the world’s leading research institutions and doctors to support FDA-authorized investigator-initiated clinical trials
Learn more about cannabidiol from the medical community and regulators
We are modernizing the way medicines are taken
Experts in drug development and delivery, manufacturing, and commercialization
Recent media coverage regarding Orcosa
Company news and announcements
Ewing, NJ – September 2, 2022 – Orcosa Inc. (“Orcosa” or the “Company”), a life sciences company modernizing the way medicines are taken through its next generation drug delivery technology – the Rapid Infusion Technology (RITe™) Platform – announced that the positive results in NYU Langone Health’s (“NYU Langone”) multicenter Phase 1/2 clinical trial utilizing Orcosa’s lead product candidate, ORAVEXX™ (cannabidiol, CBD) will be presented at the European Society for Surgery of the Shoulder and Elbow, 30th SECEC-ESSSE Congress in Dublin on September 9.
The trial, which was conducted jointly at NYU Langone and Baptist Health/Jacksonville Orthopaedic Institute, sought to evaluate safety and impact on post-operative pain, patient satisfaction and opioid consumption following arthroscopic rotator cuff repair in 99 patients.
The findings, which were recently published in The American Journal of Sports Medicine and to be presented by co-author Eoghan T. Hurley of NYU Langone, demonstrated that cannabidiol (CBD) administered utilizing the RITe™ Platform effectively reduces pain after shoulder surgery with no safety concerns.
About ORAVEXX™
ORAVEXX™ is a non-addictive proprietary cannabidiol composition that utilizes the RITe™ Platform to treat pain and has the potential to provide a safe, alternative treatment option to opioids and NSAIDs. Historically, research on the effects of CBD has been limited by a variety of issues including inaccurate dosing, low bioavailability, difficult administration, and a lack of GMP-manufactured products with matching placebos with which to conduct clinical research. ORAVEXX™ is being developed to address these issues associated with unreliable and inefficient orally delivered CBD and provide researchers the opportunity to evaluate CBD more accurately in clinical trials.
About Orcosa Inc.
Orcosa Inc. is a life sciences company modernizing the way medicines are taken and improving patient outcomes through its proprietary therapeutic delivery technology, the Rapid Infusion Technology (RITe™) Platform. Orcosa is the inventor, developer and exclusive owner of the RITe™ Platform, a fast acting, easy-to-take tablet engineered to enhance drug absorption. Orcosa’s lead program, ORAVEXX™, is a non-addictive proprietary cannabidiol composition that utilizes the RITe™ Platform to treat pain and has the potential to provide a safe, alternative treatment option to opioids and NSAIDs. The company is currently supporting FDA-authorized clinical trials at leading American research institutions to evaluate the safety and effectiveness of ORAVEXX™ for pain management. For more information on Orcosa, please visit https://www.orcosa.com/.
Forward-Looking Statements
Certain statements made herein constitute “forward-looking statements”. These forward-looking statements include, but are not limited to, the development of ORAVEXX™ and the RITe™ Platform. These statements are based on the current expectations of Orcosa and are not predictions of actual performance. Such forward-looking statements involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Orcosa to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.
Media Contact:
FGS GlobalDevin Brodadevin.broda@fgsglobal.com212-687-8080
Investor Contact:
IR@orcosa.com